Go to the list of all blogs
Anna G's Avatar
published in Blogs
Nov 28, 2022
Biogen (BIIB, $291.61) shares slump, amidst reports of patient death in Eisai Alzheimer's death

Biogen (BIIB, $291.61) shares slump, amidst reports of patient death in Eisai Alzheimer's death

Biogen  shares plunged on Monday, following reports that a woman who participated in a trial of the drugmaker's developing Alzheimer's treatment died due to a brain hemorrhage. The company is developing the drug with  Eisai Co.

According to Science.org, the case involved a 65-year-old woman who died of a massive brain hemorrhage following a stroke and a type of brain swelling and bleeding in a trial of Eisai. The report mentioned that the bleeding started after the patient received an anti-clotting drug.

Biogen and Eisai have published very limited data from the trial. More results are expected to be presented at a conference this week.

Related Ticker: BIIB

BIIB's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for BIIB moved out of overbought territory on August 20, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 21 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIIB as a result. In 59 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.

The Moving Average Convergence Divergence Histogram (MACD) for BIIB turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 61 similar instances when the indicator turned negative. In 43 of the 61 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.

BIIB broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 36 of 58 cases where BIIB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.

Following a +0.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 160 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.

The Aroon Indicator entered an Uptrend today. In 107 of 180 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.689) is normal, around the industry mean (19.050). P/E Ratio (38.277) is within average values for comparable stocks, (34.258). Projected Growth (PEG Ratio) (2.221) is also within normal values, averaging (5.614). BIIB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.025). P/S Ratio (3.189) is also within normal values, averaging (4.033).

The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 197.52B. The market cap for tickers in the group ranges from 4.8K to 1.03T. LLY holds the highest valuation in this group at 1.03T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 15%. MIRA experienced the highest price growth at 8%, while GRFS experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 178%. For the same stocks of the Industry, the average monthly volume growth was 32% and the average quarterly volume growth was -23%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 26
P/E Growth Rating: 55
Price Growth Rating: 52
SMR Rating: 59
Profit Risk Rating: 63
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
BIIB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders

Industry PharmaceuticalsMajor

Profile
Details
Industry
Biotechnology
Address
225 Binney Street
Phone
+1 617 679-2000
Employees
7500
Web
https://www.biogen.com
Interact to see
Advertisement
VIA fell over 11% today, extending a slide that began last week; the stock has been under pressure since trading around the high‑teens and low‑$20s, well below its $46 IPO price.
LAES fell more than 19% today as the market digested a $125 million registered direct offering of 30.4 million new shares (or pre‑funded warrants) plus warrants for up to 60.8 million additional shares, all priced at $4.11 per unit.
Shares of ALDX are down about 73.02% in premarket trading, plunging from a prior close near 4.13 dollars to roughly 1.11 dollars after a major regulatory setback. The collapse follows fresh confirmation that the U.S. Food and Drug Administration has again declined to approve reproxalap for dry eye disease, issuing another Complete Response Letter that questions efficacy.
Shares of MVST are down about 25% in premarket trading today compared with the prior close. The slide follows a sharp reassessment of the company’s outlook as investors react to new information and recent volatility in high‑beta battery and EV names.
Solaris Energy Infrastructure’s stock SEI jumped roughly 13% in today’s session, extending a sharp recent rebound from early-March lows. The move is driven by ongoing post-earnings momentum after strong Q4 and full‑year 2025 results and raised guidance highlighted rapid growth in its power solutions business.
Shares of LMND are trading approximately +10% higher intraday on Tuesday, March 17, 2026, rising from a prior close of $57.74 to around $63.51. Primary catalyst: Morgan Stanley upgraded LMND to an 'Overweight' rating and raised its price target to $85 from $80.
Shares of ICHR surged approximately +15% intraday on Tuesday, March 17, 2026, trading near $48.98 versus a prior closing price of $42.59. The primary catalyst is a high-profile analyst upgrade by Stifel, with analyst Brian Chin upgrading the stock to Buy citing improved cyclical strength and conviction in the company's revenue and margin trajectory.
NBIS shares are down approximately 10.00% in Tuesday's session, falling from a prior close of $129.85 to around $116.87. The primary catalyst is Nebius Group's pre-market announcement of a proposed $3.75 billion convertible senior notes offering, sparking dilution concerns.
TME shares fell over 20% today, with the stock sliding from the mid‑$15s toward the low‑$13s in the wake of its Q4 2025 report and earnings call, extending a pre‑market drop of roughly 12–13%.
HUYA shares fell over 11% today, dropping from the mid‑$3 range toward the low‑$3s following the company’s Q4 2025 earnings release before the U.S. market open. Q4 total net revenues rose about 16% year over year to roughly CNY 1.74 billion, with full‑year 2025 revenues up around 7% to CNY 6.5 billion, but the market had already priced in a rebound after a difficult 2024.​
CWCO fell over 9% today, trading around the low‑$31 range versus recent levels in the mid‑$30s to near $39, as the market reacted negatively to Q4 2025 results and forward commentary. Full‑year 2025 results showed stable earnings and dividend growth but a roughly 9% decline in services revenue to about $46.3 million, reflecting a slowdown in project‑based construction work.
SMTC shares dropped over 8% today after the company reported Q4 results that met or modestly beat Street estimates but showed the slowest year‑over‑year revenue growth in several quarters, at about 9.3% to roughly $274–275 million.
AXTI shares slipped more than 6% today, reversing part of a powerful rally that had recently driven the stock to a 52‑week high above $47 and more than doubled its price year‑to‑date. Q4 2025 revenue of about $23.0 million missed consensus by roughly $1.2 million and fell 8–18% year over year and sequentially, while the company posted another GAAP net loss of around $3.5 million (–$0.08 per share).
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
Shares of KC surged approximately +17% in premarket trading on March 18, 2026, from a prior close of $13.12 to approximately $15.35. The primary catalyst is Kingsoft Cloud's release of its unaudited Q4 and full-year 2025 financial results before the U.S. market open, which appear to have significantly exceeded analyst expectations.
AngloGold Ashanti (AU) shares tumbled approximately 7% in premarket trading on March 18, 2026, extending a multi-week downtrend that has erased nearly 20% of the stock's value since late January highs. The primary catalyst driving the decline is persistent investor concern over AngloGold's lowered 2026 production guidance, with the company projecting gold output of 2.80–3.17 million ounces — a roughly 3% decline from its 2025 production of 3.1 million ounces.
AAOI shares surged approximately 10.90% in premarket trading on March 18, 2026, rising from a prior close of $86.33 to $95.74. The primary catalyst is strong positive sentiment generated at OFC 2026 — the Optical Fiber Communications Conference and Exhibition — where Applied Optoelectronics unveiled breakthrough laser and transceiver technology for next-generation AI data center infrastructure.
LITE shares surged approximately +12% in early Wednesday trading on March 18, 2026, with the stock changing hands near $727 compared to a prior session close of $649.56. The primary near-term catalyst is Lumentum's S&P 500 index inclusion, effective March 23, 2026, triggering front-running by institutional investors and mandatory buying by passive index funds.
Shares of New Era Energy & Digital, Inc. (NUAI) are trading down approximately 17% during today's session, with the prior close sitting at $5.56. The decline follows the company's March 17 business update conference call and webcast, held after market hours, during which management discussed the recently filed fiscal year 2025 annual report (Form 10-K).
Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.